FDA to assess Teva's biologics application for Neutroval

02/2/2010 | Reuters

The FDA will evaluate Teva Pharmaceutical Industries' biologics-license application for XM02, a white blood cell booster and a follow-on version of Amgen's Neupogen, the company announced. In its filing, Teva stated that it plans to market the drug as Neutroval.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA